CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline

Bernstein Liebhard reminded Capricor Therapeutics investors of a September 28, 2026 deadline in a securities-fraud class action against the company. The notice creates legal and reputational risk for Capricor, though it provides no allegations, damages estimate, or operational update.

Analysis

This is primarily a litigation-overhang signal rather than a fundamental re-rating catalyst. Plaintiff-law-firm deadline notices rarely change expected liability absent a new complaint, lead-plaintiff filing with substantive allegations, insurance disclosure, or an adverse ruling; the immediate effect is more likely incremental retail selling and wider borrow/option implied volatility than a durable change in enterprise value. For CAPR, the relevant sensitivity is financing: any sustained equity weakness could raise dilution risk if clinical development requires capital before a material partnership, regulatory, or trial-data catalyst.

The market may overreact if the underlying allegations concern disclosure timing rather than independently verifiable clinical efficacy, safety, manufacturing, or regulatory conduct. Over the next 1-3 months, monitor cash runway, shelf-registration/ATM activity, insider transactions, FDA correspondence, and whether management modifies development timelines; these are more consequential than the litigation notice itself. A 6-18 month downside scenario requires litigation to impair capital access or reveal a fundamental issue, while dismissal, modest insured settlement, or clean clinical/regulatory execution would remove the overhang.

There is no high-conviction directional trade solely from this item. The better setup is event-driven: litigation-related volatility can create an entry opportunity only after verifying that cash runway and the core clinical thesis remain intact, while a new financing filing or adverse regulatory disclosure would justify reassessing downside exposure.

Key Decisions for Investors

• Do not initiate a standalone CAPR short on this notice; legal-advertisement headlines have weak predictive value for damages or operating outcomes. Reassess only if a detailed lead-plaintiff complaint identifies new clinical, manufacturing, or regulatory facts not previously disclosed.
• Set a 1-3 month alert for CAPR S-3, ATM, 8-K financing, or cash-runway guidance changes. A discounted equity raise following litigation-driven weakness would increase dilution risk and could warrant a tactical short or avoidance of long exposure.
• For existing CAPR longs, reduce gross exposure or use defined-risk puts through the next material corporate update if position sizing assumes uninterrupted access to equity capital; remove the hedge if management confirms runway through the next major clinical/regulatory catalyst without new dilution.
• Consider a post-volatility long only if shares decline materially without new fundamental disclosures and diligence confirms no change in trial timelines, FDA status, or cash runway. Thesis is falsified by adverse clinical/regulatory information or financing that meaningfully expands the share count.